Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study

Table 2 Energy expenditure and respiratory quotients of ziprasidone and olanzapine-treated patients (n = 10 per group)

	Ziprasidone start	Ziprasidone end		Olanzapine start	Olanzapine end		Ziprasidone change (%)^a	Olanzapine change (%)^a
Measure	Median (IQR)	Median (IQR)	P^b	Median (IQR)	Median (IQR)	P^b	Median (IQR)	Median (IQR)	P^c
Absolute REE (kcal/24 hr)	1075.20 (1024.78, 1416.81)	1132.38 (1006.71, 1723.06)	0.678	1630.24 (1079.23, 1898.10)	1255.40 (1069.48, 1747.83)	0.241	1.41 (−11.98, 61.96)	−5.27 (−33.37, 10.58)	0.369
REE normalized to LBM (kcal/g)	18.29 (16.68, 22.39)	24.47 (22.48, 37.13)	0.011^*	27.36 (19.91, 35.36)	27.60 (23.46, 34.85)	0.445	37.78 (18.36, 83.14)	17.17 (−17.47, 36.36)	0.072
Respiratory Quotient	0.82 (0.76, 0.88)	0.84 (0.80, 0.92)	0.262	0.86 (0.81, 1.01)	0.87 (0.82, 0.92)	0.574	5.81 (−3.33, 14.40)	−4.64 (−13.31, 13.27)	0.288

IQR Interquartile Range, REE Resting Energy Expenditure, LBM, LBM.
^a, $\frac{(posttreatment - baseline)}{baseline}$ * 100; ^b,Wilcoxon signed rank test; ^c, Kruskal-Wallis H test; ^*, p < 0.05.

ISSN: 1744-9081